Background and Aims:LPAR6 is the most recently deter-mined G protein-coupled receptor of lysophosphatidic acid,and hardly any study has demonstrated the performance of LPAR6 in cancers.We sought to clarify the relatio...Background and Aims:LPAR6 is the most recently deter-mined G protein-coupled receptor of lysophosphatidic acid,and hardly any study has demonstrated the performance of LPAR6 in cancers.We sought to clarify the relationship of LPAR6 to prognosis potential and tumor infiltration im-mune cells in different cancers.Methods:The expression of LPAR6 and its clinical characteristics were evaluated on various databases.The association between LPAR6 and im-mune infiltrates of various types of cancer were investigated via TIMER.Results:We determined that higher LPAR6 ex-pression level was associated with a better overall survival.Additionally,high LPAR6 expression level was significantly associated with better disease-specific survival(DSS)in bladder cancer,and better overall survival(OS)/progres-sion-free survival(PFS)/distant metastasis-free survival(DMFS)/relapse-free survival(RFS)in breast cancer and some other types of cancers.Moreover,LPAR6 significant-ly affects the prognosis of various cancers via The Cancer Genome Atlas(TCGA).Further research exposed that the mRNA level of LPAR6 was positively coordinated with in-filtrating levels of devious immune cells in hepatocellular carcinoma.Conclusions:Our results imply that LPAR6 is associated with prognosis potential and immune infiltration levels in liver cancer.Moreover,LPAR6 expression possibly contributes to the activation of CD8+T,naive T,effector T cells and natural killer cells and inactivates T regulatory cells,decreases T cell exhaustion and regulate T helper cells in liver cancer.These discoveries imply that LPAR6 could be a novel biomarker of prognosis for indicating progno-sis potential and immune-infiltrating level in hepatocellular carcinoma.展开更多
基金This study was supported by grants from the National Natural Science Foundation(81630086,82030099)the National Key R&D Program of China(2018YFC2000700)+3 种基金Shanghai Public Health System Construction Three-Year Action Plan(GWV-10.1-XK15)Innovative research team of high-level local universities in Shanghai for H.W.and the National Science Foundation of China(NSFC81702730)the Start-up Plan for New Young Teacher of SHSMU(KJ30214190026)of JH.
文摘Background and Aims:LPAR6 is the most recently deter-mined G protein-coupled receptor of lysophosphatidic acid,and hardly any study has demonstrated the performance of LPAR6 in cancers.We sought to clarify the relationship of LPAR6 to prognosis potential and tumor infiltration im-mune cells in different cancers.Methods:The expression of LPAR6 and its clinical characteristics were evaluated on various databases.The association between LPAR6 and im-mune infiltrates of various types of cancer were investigated via TIMER.Results:We determined that higher LPAR6 ex-pression level was associated with a better overall survival.Additionally,high LPAR6 expression level was significantly associated with better disease-specific survival(DSS)in bladder cancer,and better overall survival(OS)/progres-sion-free survival(PFS)/distant metastasis-free survival(DMFS)/relapse-free survival(RFS)in breast cancer and some other types of cancers.Moreover,LPAR6 significant-ly affects the prognosis of various cancers via The Cancer Genome Atlas(TCGA).Further research exposed that the mRNA level of LPAR6 was positively coordinated with in-filtrating levels of devious immune cells in hepatocellular carcinoma.Conclusions:Our results imply that LPAR6 is associated with prognosis potential and immune infiltration levels in liver cancer.Moreover,LPAR6 expression possibly contributes to the activation of CD8+T,naive T,effector T cells and natural killer cells and inactivates T regulatory cells,decreases T cell exhaustion and regulate T helper cells in liver cancer.These discoveries imply that LPAR6 could be a novel biomarker of prognosis for indicating progno-sis potential and immune-infiltrating level in hepatocellular carcinoma.
